• Product nameAnti-VEGF Receptor 2 antibody [3D09]
    See all VEGF Receptor 2 primary antibodies
  • Description
    Rat monoclonal [3D09] to VEGF Receptor 2
  • SpecificityThis antibody shows no cross-reactivity with VEGF Receptor 1.
  • Tested applicationsSuitable for: WB, IP, Functional Studiesmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    Purified fragment, corresponding to N terminal amino acids 30-200 of Mouse VEGF Receptor 2

  • Positive control
    • Mouse skin endothelial cells (mSENDs)


Our Abpromise guarantee covers the use of ab42230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent dilution. Predicted molecular weight: 153 kDa.
IP Use at an assay dependent dilution.
Functional Studies Use a concentration of 1 - 5 µg/ml. Can induce VEGF Receptor 2 tyrosine phosphorylation in mouse skin endothelial cells.


  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD309 antibody
    • CD309 antigen antibody
    • EC antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Anti-VEGF Receptor 2 antibody [3D09] images

  • Mouse skin endothelial cells (mSENDs) were stimulated with ab42230 or VEGF for 30min. Phospho-VEGF Receptor 2 was detected with and anti-phosphotyrosine antibody.

References for Anti-VEGF Receptor 2 antibody [3D09] (ab42230)

This product has been referenced in:

See 1 Publication for this product

Product Wall

Thank you for your reply. I have now returned to the office an hope I can help further with your enquiry.

I can now confirm that of the antibodies we have directed against VEGF Receptor 2 (that are not raised in rabbit), most likely to react w...

Read More

Thank you for your message which has been forwarded to me as Karin is currently away from the office.

Reviewing the correspondence on this enquiry so far, I notice Karin has selected some antibodies not raised in rabbit and has been in conta...

Read More